{"id":"W3164016623","doi":"10.1136/annrheumdis-2021-eular.2115","title":"OP0172 BRENTUXIMAB VEDONTIN FOR SKIN INVOLVEMENT IN REFRACTORY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS, INTERIM RESULTS OF A PHASE IIB OPEN-LABEL TRIAL","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Systemic Sclerosis and Related Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"Windsor Regional Hospital; Western University","funders":"Regeneron Pharmaceuticals; Samsung; Genentech; Acceleron; Cumberland Pharmaceuticals; Eli Lilly and Company; CSL Behring; Medpace; Biogen; Gilead Sciences; Amgen; Pfizer","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Rituximab; Clinical endpoint; Scleroderma (fungus); Gastroenterology; Surgery; Clinical trial; Lymphoma; CD30; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002283749,0.001670439,0.002344372,0.0003014262,0.0003856093,0.001874603,0.0009307726,0.001602495,0.00539391],"category_scores_gemma":[0.001235567,0.0004188684,0.001875685,0.0002940351,0.0008711275,0.001222576,0.0003248298,0.003728943,0.001621769],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008401521,"about_ca_system_score_gemma":0.00107169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00109231,"about_ca_topic_score_gemma":0.002715994,"domain_scores_codex":[0.9993995,0.0002444008,0.00002965479,0.00006723434,0.00005726984,0.0002018688],"domain_scores_gemma":[0.9991593,0.0002313537,0.0001213858,0.00006050805,0.00005791332,0.0003694965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7790437,0.01195601,0.002836494,0.001995448,0.002542965,0.0005247906,0.0002554829,0.002542852,0.01698861,0.0009143013,0.01335866,0.1670408],"study_design_scores_gemma":[0.85975,0.1231046,0.006750513,0.0001981853,0.000698042,0.0003462833,0.00009325049,0.001518172,0.00164505,0.0006381923,0.005212498,0.00004518292],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9643305,0.01559489,0.001536698,0.002247321,0.0008918763,0.002215059,0.003464934,0.0003759711,0.009342711],"genre_scores_gemma":[0.9678352,0.006386511,0.002366077,0.003758461,0.0005957327,0.002730425,0.00739058,0.00008644877,0.008850639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00539391,"threshold_uncertainty_score":0.01804447,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1539483457360499,"score_gpt":0.379412997237523,"score_spread":0.2254646515014731,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}